These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21646472)

  • 21. [Molecular mechanism of cisplatin to enhance the ability of TRAIL in reversing multidrug resistance in gastric cancer cells].
    Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):404-11. PubMed ID: 26463141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
    Paillas S; Boissière F; Bibeau F; Denouel A; Mollevi C; Causse A; Denis V; Vezzio-Vié N; Marzi L; Cortijo C; Ait-Arsa I; Askari N; Pourquier P; Martineau P; Del Rio M; Gongora C
    Cancer Res; 2011 Feb; 71(3):1041-9. PubMed ID: 21159664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
    Chintala S; Tóth K; Cao S; Durrani FA; Vaughan MM; Jensen RL; Rustum YM
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):899-911. PubMed ID: 20066420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of preventive and therapeutic activity of novel non-steroidal anti-inflammatory drug, CG100649, in colon cancer: Increased expression of TNF-related apoptosis-inducing ligand receptors enhance the apoptotic response to combination treatment with TRAIL.
    Woo JK; Kang JH; Jang YS; Ro S; Cho JM; Kim HM; Lee SJ; Oh SH
    Oncol Rep; 2015 Apr; 33(4):1947-55. PubMed ID: 25672292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The BH3-mimetic obatoclax reduces HIF-1α levels and HIF-1 transcriptional activity and sensitizes hypoxic colon adenocarcinoma cells to 5-fluorouracil.
    Gariboldi MB; Taiana E; Bonzi MC; Craparotta I; Giovannardi S; Mancini M; Monti E
    Cancer Lett; 2015 Aug; 364(2):156-64. PubMed ID: 25979228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
    To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
    Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents.
    Vasilevskaya IA; Selvakumaran M; Hierro LC; Goldstein SR; Winkler JD; O'Dwyer PJ
    Clin Cancer Res; 2015 Sep; 21(18):4143-52. PubMed ID: 26023085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
    Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H
    J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis.
    Beurel E; Kornprobst M; Blivet-Van Eggelpoël MJ; Cadoret A; Capeau J; Desbois-Mouthon C
    Int J Oncol; 2005 Jul; 27(1):215-22. PubMed ID: 15942663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of glycogen synthase kinase-3 beta induces apoptosis and mitotic catastrophe by disrupting centrosome regulation in cancer cells.
    Yoshino Y; Ishioka C
    Sci Rep; 2015 Aug; 5():13249. PubMed ID: 26292722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells.
    Kunnimalaiyaan M; Vaccaro AM; Ndiaye MA; Chen H
    Mol Cancer Ther; 2007 Mar; 6(3):1151-8. PubMed ID: 17363508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression.
    Harashima N; Takenaga K; Akimoto M; Harada M
    Oncotarget; 2017 Jun; 8(26):42887-42900. PubMed ID: 28476028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R; Bedi A
    Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of hypoxia inducible factor-1α downregulates the expression of epithelial to mesenchymal transition early marker proteins without undermining cell survival in hypoxic lens epithelial cells.
    Cammarata PR; Neelam S; Brooks MM
    Mol Vis; 2015; 21():1024-35. PubMed ID: 26392741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
    Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation.
    Fu QH; Zhang Q; Zhang JY; Sun X; Lou Y; Li GG; Chen ZL; Bai XL; Liang TB
    Tumour Biol; 2016 Jun; 37(6):7277-86. PubMed ID: 26666823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
    Jia X; Hong Q; Lei L; Li D; Li J; Mo M; Wang Y; Shao Z; Shen Z; Cheng J; Liu G
    Oncotarget; 2015 Apr; 6(11):8648-62. PubMed ID: 25929338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.
    Sapra P; Kraft P; Pastorino F; Ribatti D; Dumble M; Mehlig M; Wang M; Ponzoni M; Greenberger LM; Horak ID
    Angiogenesis; 2011 Sep; 14(3):245-53. PubMed ID: 21452059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of GSK-3β reverses the pro-apoptotic effect of proadifen (SKF-525A) in HT-29 colon adenocarcinoma cells.
    Jendželovský R; Koval J; Mikeš J; Papčová Z; Plšíková J; Fedoročko P
    Toxicol In Vitro; 2012 Sep; 26(6):775-82. PubMed ID: 22683934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of cyclin A kinase activity in E2F-1 chemogene therapy of colon cancer.
    Elliott MJ; Baker JD; Dong YB; Yang HL; Gleason JF; McMasters KM
    Tumour Biol; 2002; 23(6):324-36. PubMed ID: 12677090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.